Amycretin: Reference Overview and Reconstitution Notes

Amycretin is a single molecule that activates two cell receptors linked to appetite and energy use. It is still being studied in research settings and has not been approved by the FDA.

Amycretin

What it is

Amycretin, also known by the lab code NN9487, is a peptide (a small protein-like molecule) that acts as a single-molecule agonist. Think of an agonist like a key that fits into a lock and turns it on. Amycretin fits two different locks at once: the GLP-1 receptor and the amylin receptor. Both of these are proteins on cells that help control appetite and how the body uses energy. It is being developed in two forms: one injected just under the skin, and one taken by mouth.

Research context and categorization

Mechanism and Classification

Amycretin falls into the metabolic and weight regulation category. Metabolism is simply the set of processes the body uses to turn food into energy. Both the GLP-1 receptor and the amylin receptor send signals related to appetite and energy use. Because this molecule targets both receptors at the same time, researchers group it with metabolic compounds rather than with other types of research peptides.

Investigational Scope and Limitations

In published research, Amycretin is studied in the context of body weight reduction and blood sugar control. One measure researchers look at is HbA1c, which is a way to see what average blood sugar levels have been over roughly the past three months. Researchers are interested in whether targeting both the GLP-1 and amylin receptors at the same time offers an advantage over targeting only the GLP-1 receptor.

These uses are strictly investigational, meaning they are only being studied in labs and research trials. Amycretin has not been approved for any use, and the results seen in early-phase and phase 2 studies are not confirmed or established benefits.

Status

• Regulatory status: Investigational, not FDA-approved. As of mid-2026, it has been studied through early-phase and phase 2 trials (small-scale research studies), and a larger phase 3 program is planned. It currently has no approved use, no prescribing route, and no compounding pathway (no legal way to have it prepared by a pharmacist).
• Sport status: Prohibited under the WADA Prohibited List. WADA (the World Anti-Doping Agency) sets the rules on banned substances in sport. Because Amycretin has no current regulatory approval for human use, it falls under the S0 category (Non-Approved Substances). Because it is a peptide that activates hormone receptors, it is closely related to the S2 class (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes subject to WADA or USADA rules should treat it as banned.

Reconstitution notes (general)

For a lyophilized (freeze-dried) research peptide supplied as a powder, concentration is calculated using a simple formula:

• Concentration Formula: Milligrams of peptide in the vial divided by the millilitres of bacteriostatic water added. Bacteriostatic water is regular water with a small preservative added to stop bacteria from growing in the vial.
• Example: Adding 2 mL of bacteriostatic water to 10 mg of powder gives a solution with a concentration of 5 mg/mL.

To safely dissolve the powder, follow these steps:

1. Add the water slowly down the inner wall of the vial rather than spraying it directly onto the powder.
2. Swirl or gently roll the vial until the contents are fully dissolved. Do not shake.

You can work out specific volumes with the calculator at peptide calculator.

Dilution and handling notes (compound-specific)

Oral vs. Injectable Presentations

Amycretin comes in two forms, and each is handled differently. The oral form is a solid, tablet-style unit. It is not reconstituted and does not involve a bacteriostatic water step, so the powder reconstitution notes below do not apply to it. Do not try to dissolve an oral unit as if it were an injectable.

Key point: The amylin part of Amycretin is highly amyloidogenic, meaning it tends to clump together (similar to how tiny sugar crystals stick to each other and grow). This makes the reconstituted solution prone to clumping and requires careful handling and a more dilute concentration.

Managing Aggregation Risks

Amylin and similar molecules are known to clump together in solution, a process called aggregation. When this happens, you may notice the liquid turning cloudy, taking on a gel-like or stringy texture, or developing tiny solid bits. The risk of clumping rises as the concentration increases and as the solution sits longer.

To lower these risks, use the following practical steps:

• Dilute generously: Keep the reconstituted concentration on the dilute side. Using a larger volume of diluent (the liquid used to dissolve the powder) per vial is often better than using the smallest possible amount.
• Handle gently: Add the diluent slowly along the glass wall of the vial. Swirl gently and do not shake, as shaking and foaming can start the clumping process.
• Allow to rest: Let the vial sit briefly at room temperature to allow full dissolution before putting it in the refrigerator.

If the material gels, stays persistently cloudy, or shows visible particles that do not clear with gentle mixing over several minutes, it should not be used. As with other peptides, protect it from light and avoid repeated warming and cooling cycles.

Handling and storage

To keep the material stable, follow these standard storage guidelines:

• Store the reconstituted solution in the refrigerator at 2 to 8 C and keep it away from light.
• Wipe the rubber stopper with an alcohol swab before each access, and write the reconstitution date on the vial label.
• Reconstituted peptides are generally usable for about four weeks when stored in the refrigerator.

Always inspect the vial before use. Discard any solution that has turned cloudy, changed color, or contains floating bits or particles.

Related reading

• ARA-290
• Cagrilintide
• Ecnoglutide
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What receptors does Amycretin target and how is it classified?

Amycretin is a single-molecule agonist that simultaneously activates the GLP-1 receptor and the amylin receptor, placing it in the metabolic and weight-regulation research category.

Is Amycretin FDA-approved or permitted in sport?

No. As of mid-2026 it remains strictly investigational (through phase 2), with no FDA approval, no prescribing route, and no compounding pathway. WADA prohibits it under S0 (Non-Approved Substances) and S2 (Peptide Hormones/Mimetics).

How is a lyophilized Amycretin research vial reconstituted?

Divide the vial's milligram content by the milliliters of bacteriostatic water added to get mg/mL (e.g., 10 mg ÷ 2 mL = 5 mg/mL). Add water slowly down the inner vial wall, then swirl gently until dissolved.

What the research community gets wrong about Amycretin

Amycretin (lab code NN9487) gets treated like a plain GLP-1 peptide at the bench. It is not, and a few common assumptions can waste a vial. Here are the ones worth correcting.

• It is not just a GLP-1 peptide. Amycretin activates both the GLP-1 receptor and the amylin receptor in one molecule. The amylin part is the reason it behaves differently in the vial than a single-target GLP-1 analog.
• "Single molecule" does not mean simple to handle. The amylin portion is amyloidogenic, which means it tends to clump (aggregate) in solution. That risk goes up as concentration goes up and as the solution sits longer, so a more dilute prep is usually the safer choice.
• Cloudy or gel-like liquid is not "undissolved powder." With an amylin-type molecule, haze, stringiness, or tiny solid bits often mean aggregation has started. Shaking harder to "mix it in" makes it worse, because foaming and air contact drive clumping.
• Not every form is reconstituted. Amycretin is studied as both an injectable and a solid oral unit. The oral solid is not dissolved in bacteriostatic water. Treating it like an injectable powder is a mistake.
• It is investigational, so there is no standard vial. Amycretin has no approved product and no set label, so milligram content per vial can vary by supplier. Always calculate concentration from the actual amount stated on your vial rather than assuming a value.

From our bench: If you have reconstituted an Amycretin research vial, we want your real numbers. At what mg/mL concentration did your solution first show haze or stringiness, and how many days did a clear prep hold at 2 to 8 C before any cloudiness appeared? Note your diluent volume, whether you swirled or let it rest, and what the vial looked like when you called it unusable. Send only measurements you actually recorded, no estimates.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1 trial. The Lancet (2025). PubMed PMID 40550229
5. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. The Lancet (2025). PubMed PMID 40550231
6. The effect of amycretin, a unimolecular GLP-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. eBioMedicine (2025). PMC12309853